drugset / Trial / NCT02151409
Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Europe. The aim of this trial is to develop a complement system targeted monoclonal antibody (mAb) to be used in treatment of subjects with chronic autoimmune diseases.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-10
- Completion
- 2009-10
Publications
- Results The first-in-human trial of the humanised monoclonal antibody NNC 0151-0000-0000 blocking the C5a receptor (C5aR). EULAR (European League Against Rheumatism) 2009; Country: Denmark City: Copenhagen
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NNC 0151-0000-0000 | Other / unclassified | — | Intravenous |